Pluristem gets 26th patent

Pluristem Therapeutics (PSTI +6.6%) has received a patent for the treatment of peripheral artery disease with "placental-derived adherent stromal cells."

The expiry of the IP is 2028.

The patent is the 26th that the developer of cell-therapy products has received. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs